Recent Pfizer Press Releases

  • 5/25/17 1:16 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company’s proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent (ESA) has been recommended for approval by a U.S. FDA Advisory Committee. The Committee’s favorable recommendation was based on itsmore...
  • 5/24/17 6:45 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation of Ontario, Canada to purchase up to 4 million shares of Pfizer common stock at a price of $31.60 per share in cash. TRC Capital’s offer price of $31.60 per share is approximately 4.27 percent lower than the $33.01 closing share price of Pfizer’s common stock on May 12, 2017 – the business day prior to the date of themore...
  • 5/17/17 8:00 pm EDT

    Data to be presented on more than 15 clinical-stage assets in both solid and hematologic tumors

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it will present more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 mechanisms of action, at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 2-6, 2017. New data will be featured in nine oral presentations from company-sponsored clinical trials, including a late-breaker on themore...
  • 5/17/17 11:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, June 9, 2017 at 11:00 a.m. EDT. The purpose of the call is to provide an update on Pfizer’s oncology business and to review Pfizer’s ASCO data presentations. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and pre-registering for themore...
  • 5/8/17 10:00 am EDT

    Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children’s Investment Fund Foundation reduce the price of the injectable contraceptive

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children’s Investment Fund Foundation (CIFF) today announced a multi-year extension of their collaboration to further broaden access to Pfizer’s all-in-one injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in some of the world’s poorest countries. Sayana Press will now be available to qualified purchasers at a guaranteed price of US $0.85more...
  • 5/3/17 5:25 pm EDT

    Data Demonstrated Tofacitinib was Effective as Both Induction and Maintenance Therapy in the Treatment of Moderate to Severe Ulcerative Colitis

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that detailed results from the Phase 3 Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) clinical program were published in The New England Journal of Medicine (NEJM). Data from all three pivotal Phase 3 studies – OCTAVE Induction 1, OCTAVE Induction 2 and OCTAVE Sustain – met their respective primary endpoints, demonstrating that tofacitinib citrate was more effective thanmore...
  • 5/3/17 9:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) for the treatment of adult patients with active psoriatic arthritis (PsA). A separate sNDA was also accepted for XELJANZ XR® (tofacitinib citrate) extended release 11 mg once daily use in PsA. The sNDA submission is based on data frommore...
  • 5/2/17 6:45 am EDT
    • First-Quarter 2017 Revenues of $12.8 Billion, Reflecting 1% Operational Decline, Unfavorably Impacted by One Less U.S. Selling Day and Two Fewer International Selling Days Compared to the Prior-Year Quarter
    • First-Quarter 2017 Reported Diluted EPS(1) of $0.51, Adjusted Diluted EPS(2) of $0.69
    • Reaffirmed 2017 Financial Guidance
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for first-quarter 2017 and reaffirmed its 2017 financial guidance. On June 24, 2016, Pfizer acquired Anacor Pharmaceuticals, Inc. (Anacor). Therefore, financial results for first-quarter 2017 reflect three months of legacy Anacor operations, which were immaterial. On September 28, 2016, Pfizer acquired Medivation, Inc. (Medivation). Therefore, financial results for first-quartermore...
  • 4/27/17 12:30 pm EDT

    Declares 32-Cent Second-Quarter 2017 Dividend

    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 32-cent second-quarter 2017 dividend on the company’s common stock, payable June 1, 2017, to shareholders of record at the close of business on May 12, 2017. The second-quarter 2017 cash dividend will be the 314th consecutive quarterly dividend paid by Pfizer. “In 2016, we returned nearly $12.3 billion to shareholders through dividends and share repurchases,” said Ian Read, chairmanmore...
  • 4/27/17 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that its investigational next-generation ALK/ROS1 tyrosine kinase inhibitor, lorlatinib, was granted Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), previously treated with one or more ALK inhibitors. Enacted as part of the 2012 FDA Safety and Innovationmore...